Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma

Blood. 2023 May 4;141(18):2187-2193. doi: 10.1182/blood.2022016590.

Abstract

Classic Hodgkin lymphoma (cHL) is characterized by a tumor microenvironment (TME) containing inflammatory/immune cells. Follicular lymphoma, mediastinal gray zone lymphoma, and diffuse large B-cell lymphomas may show a TME containing inflammatory/immune cells, but the TMEs are quite different. In B-cell lymphomas and cHL, programmed cell death 1 (PD-1)-PD ligand 1 pathway blockade drugs differ in their effectiveness among patients with refractory/relapsed disease. Further research should explore innovative assays that could reveal which molecules influence sensitivity or resistance to therapy in an individual patient.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hodgkin Disease* / pathology
  • Humans
  • Lymphoma, Follicular*
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Mediastinal Neoplasms* / pathology
  • Tumor Microenvironment